Silence Therapeutics plc Overview
Latest ROE for Silence Therapeutics plc: -101.36% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-101.36%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Silence Therapeutics plc posts a ROE of -101.36%. That is below the Healthcare sector average of 11.15%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 11.15% is typical. Silence Therapeutics plc's -101.36% is lower that level. That is roughly 1008.7% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Silence Therapeutics plc's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -101.36%; use YoY and peer views to separate noise from signal.
Context for SLNCF's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.15%), and (3) consistency with growth and profitability. This page covers the first two; Silence Therapeutics plc's other metric pages and overview cover the third.
Judging Silence Therapeutics plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -101.36% here, then scan peer and history charts to see if the gap is persistent.
